Kairos Pharma (KAPA) Non Operating Interest Expenses (2023 - 2024)
Kairos Pharma's (KAPA) quarterly Non Operating Interest Expenses came in at $133000.0 in Q4 2024, up 4333.33% on a YoY basis from $3000.0 in Q1 2024, and down 75.23% quarter-over-quarter from $537000.0 in Q3 2024.
Powered by 
Analysis
Kairos Pharma (KAPA) Non Operating Interest Expenses (2023 - 2024) Analysis & Trends
Kairos Pharma (KAPA) has reported Non Operating Interest Expenses for 2 consecutive years, with $133000.0 the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Non Operating Interest Expenses rose 4333.33% year-over-year to $133000.0; the trailing twelve-month figure through Dec 2024 stood at $698000.0 (changed N/A YoY), and the FY2024 full-year result was $670000.0, up 1495.24% from the prior year.
- Non Operating Interest Expenses eased to $133000.0 in Q4 2024 per KAPA's latest filing, from $537000.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $537000.0 in Q3 2024 and bottomed at $3000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn | - |
| 10 | Kairos Pharma | 31.79 Mn | 26.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 133,000.00 |
| Sep 30, 2024 | 537,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 15,000.00 |